Alastair Compston

Alastair Compston's AcademicInfluence.com Rankings

Alastair Compston

Medical

#958

World Rank

#1233

Historical Rank

Neurology

#100

World Rank

#153

Historical Rank

medical Degrees

Download Badge

Medical

Why Is Alastair Compston Influential?

(Suggest an Edit or Addition)

According to Wikipedia, David Alastair Standish Compston is a British neurologist. He is an emeritus professor of neurology in the Department of Clinical Neurosciences at the University of Cambridge and an emeritus fellow of Jesus College, Cambridge.

(See a Problem?)

Alastair Compston's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

Genome-wide association study of 14,000 cases of seven common diseases and 3,000 shared controls (2007) (9208)
Genome-wide association study of 14,000 cases of seven common diseases and 3,000 shared controls (2007) (9208)
Recommended diagnostic criteria for multiple sclerosis: Guidelines from the international panel on the diagnosis of multiple sclerosis (2001) (6788)
Genetic risk and a primary role for cell-mediated immune mechanisms in multiple sclerosis (2011) (2511)
Association scan of 14,500 nonsynonymous SNPs in four diseases identifies autoimmunity variants (2007) (1421)
Risk alleles for multiple sclerosis identified by a genomewide study. (2007) (1380)
Analysis of immune-related loci identifies 48 new susceptibility variants for multiple sclerosis (2013) (1170)
Multiple sclerosis (2008) (931)
Meta-analysis of genome scans and replication identify CD6, IRF8 and TNFRSF1A as new multiple sclerosis susceptibility loci (2009) (799)
A genome screen in multiple sclerosis reveals susceptibility loci on chromosome 6p21 and 17q22 (1996) (692)
Multiple sclerosis. (2002) (655)
Genome-wide association study of CNVs in 16,000 cases of eight common diseases and 3,000 shared controls (2010) (600)
Multiple sclerosis genomic map implicates peripheral immune cells and microglia in susceptibility (2019) (589)
Autologous mesenchymal stem cells for the treatment of secondary progressive multiple sclerosis: an open-label phase 2a proof-of-concept study (2012) (562)
Monoclonal antibody treatment exposes three mechanisms underlying the clinical course of multiple sclerosis (1999) (500)
Genome-wide association study of copy number variation in 16,000 cases of eight common diseases and 3,000 shared controls (2010) (465)
McAlpine's Multiple Sclerosis (2005) (452)
Pulsed monoclonal antibody treatment and autoimmune thyroid disease in multiple sclerosis (1999) (440)
Bayesian refinement of association signals for 14 loci in 3 common diseases (2012) (416)
The Berger rhythm: potential changes from the occipital lobes in man. (2010) (351)
Heterogeneity at the HLA-DRB1 locus and risk for multiple sclerosis. (2006) (310)
A high-density screen for linkage in multiple sclerosis. (2005) (308)
Oligodendrocytes Promote Neuronal Survival and Axonal Length by Distinct Intracellular Mechanisms: A Novel Role for Oligodendrocyte-Derived Glial Cell Line-Derived Neurotrophic Factor (2003) (305)
Oligodendrocyte progenitors are present in the normal adult human CNS and in the lesions of multiple sclerosis. (1998) (302)
IL-21 drives secondary autoimmunity in patients with multiple sclerosis, following therapeutic lymphocyte depletion with alemtuzumab (Campath-1H). (2009) (284)
Class II HLA interactions modulate genetic risk for multiple sclerosis (2015) (262)
Transient increase in symptoms associated with cytokine release in patients with multiple sclerosis. (1996) (261)
Mapping of multiple susceptibility variants within the MHC region for 7 immune-mediated diseases (2009) (256)
IL2RA Genetic Heterogeneity in Multiple Sclerosis and Type 1 Diabetes Susceptibility and Soluble Interleukin-2 Receptor Production (2009) (244)
Mechanism of first-dose cytokine-release syndrome by CAMPATH 1-H: involvement of CD16 (FcgammaRIII) and CD11a/CD18 (LFA-1) on NK cells. (1996) (236)
Genetic determinants of common epilepsies: a meta-analysis of genome-wide association studies (2014) (222)
Genome-wide mega-analysis identifies 16 loci and highlights diverse biological mechanisms in the common epilepsies (2018) (213)
Negligible impact of rare autoimmune-locus coding-region variants on missing heritability (2013) (203)
The role of the CD58 locus in multiple sclerosis (2009) (200)
Multiple sclerosis (2002) (198)
Efficient generation of neural precursors from adult human skin: astrocytes promote neurogenesis from skin-derived stem cells (2004) (192)
Human autoimmunity after lymphocyte depletion is caused by homeostatic T-cell proliferation (2013) (186)
Preliminary evidence from magnetic resonance imaging for reduction in disease activity after lymphocyte depletion in multiple sclerosis (1994) (184)
A role for oligodendrocyte‐derived IGF‐1 in trophic support of cortical neurons (2001) (182)
A second major histocompatibility complex susceptibility locus for multiple sclerosis (2007) (181)
The genetics of multiple sclerosis: principles, background and updated results of the United Kingdom systematic genome screen. (1998) (177)
A Highly Enriched Niche of Precursor Cells with Neuronal and Glial Potential Within the Hair Follicle Dermal Papilla of Adult Skin (2008) (177)
The expanding genetic overlap between multiple sclerosis and type I diabetes (2009) (157)
Tau and α‐synuclein in susceptibility to, and dementia in, Parkinson's disease (2007) (155)
Resolving TYK2 locus genotype-to-phenotype differences in autoimmunity (2016) (154)
Network-based multiple sclerosis pathway analysis with GWAS data from 15,000 cases and 30,000 controls. (2013) (149)
Genes in the HLA class I region may contribute to the HLA class II-associated genetic susceptibility to multiple sclerosis. (2004) (145)
FGF-dependent generation of oligodendrocytes by a hedgehog-independent pathway (2003) (142)
Tau and alpha-synuclein in susceptibility to, and dementia in, Parkinson's disease. (2007) (135)
A Scaleable and Defined System for Generating Neural Stem Cells from Human Embryonic Stem Cells (2007) (126)
A meta-analysis of whole genome linkage screens in multiple sclerosis (2003) (122)
The mesenchymal stem cells in multiple sclerosis (MSCIMS) trial protocol and baseline cohort characteristics: an open-label pre-test: post-test study with blinded outcome assessments (2011) (117)
A whole genome screen for linkage disequilibrium in multiple sclerosis confirms disease associations with regions previously linked to susceptibility. (2002) (116)
The significance of the association between HLA and multiple sclerosis. (1978) (115)
The Multiple Sclerosis Genomic Map: Role of peripheral immune cells and resident microglia in susceptibility (2017) (113)
Cognitive presentation of multiple sclerosis: evidence for a cortical variant (2003) (110)
Refining genetic associations in multiple sclerosis (2008) (108)
Comprehensive follow-up of the first genome-wide association study of multiple sclerosis identifies KIF21B and TMEM39A as susceptibility loci (2009) (107)
Guidance of oligodendrocytes and their progenitors by substratum topography. (1995) (106)
Empirical genomewide significance levels established by whole genome simulations (1997) (102)
Nonactivated microglia promote oligodendrocyte precursor survival and maturation through the transcription factor NF‐κB (2001) (102)
A genome screen for multiple sclerosis in Sardinian multiplex families (2001) (99)
Low-Frequency and Rare-Coding Variation Contributes to Multiple Sclerosis Risk (2018) (98)
Activin/Nodal Inhibition Alone Accelerates Highly Efficient Neural Conversion from Human Embryonic Stem Cells and Imposes a Caudal Positional Identity (2009) (97)
Progressive lenticular degeneration: a familial nervous disease associated with cirrhosis of the liver, by S. A. Kinnier Wilson, (From the National Hospital, and the Laboratory of the National Hospital, Queen Square, London) Brain 1912: 34; 295-509. (2009) (97)
Review: Glial lineages and myelination in the central nervous system (1997) (97)
Genetic epidemiology of multiple sclerosis. (1997) (95)
APOE epsilon variation in multiple sclerosis susceptibility and disease severity (2006) (89)
Campath-1H treatment of multiple sclerosis: lessons from the bedside for the bench (2004) (88)
Enhancing linkage analysis of complex disorders: an evaluation of high-density genotyping. (2004) (86)
A genome-wide screen for linkage in Nordic sib-pairs with multiple sclerosis (2002) (86)
Lymphocyte subpopulations in patients with multiple sclerosis. (1983) (84)
A Novel Role for Sema3A in Neuroprotection from Injury Mediated by Activated Microglia (2006) (83)
A genome screen for multiple sclerosis in Italian families (2001) (81)
High Yields of Oligodendrocyte Lineage Cells from Human Embryonic Stem Cells at Physiological Oxygen Tensions for Evaluation of Translational Biology (2013) (78)
Different pathways for iNOS‐mediated toxicity in vitro dependent on neuronal maturation and NMDA receptor expression (2002) (77)
DOUBLE-BLIND CONTROLLED TRIAL OF IMMUNOSUPPRESSION IN THE TREATMENT OF MULTIPLE SCLEROSIS: FINAL REPORT (1982) (76)
Decreased iNOS synthesis mediates dexamethasone‐induced protection of neurons from inflammatory injury in vitro (2003) (75)
The pathogenesis of demyelinating disease: insights from cell biology (1991) (75)
Suggestive evidence for association of human chromosome 18q12-q21 and its orthologue on rat and mouse chromosome 18 with several autoimmune diseases. (2001) (75)
Automated Mechanical Passaging: A Novel and Efficient Method for Human Embryonic Stem Cell Expansion (2006) (72)
The 150th anniversary of the first depiction of the lesions of multiple sclerosis. (1988) (72)
IL12A, MPHOSPH9/CDK2AP1 and RGS1 are novel multiple sclerosis susceptibility loci (2010) (72)
Genetic variation in the IL7RA/IL7 pathway increases multiple sclerosis susceptibility (2010) (70)
A genome screen for linkage in Australian sibling-pairs with multiple sclerosis (2002) (70)
Chapter 6 – The symptoms and signs of multiple sclerosis (2006) (69)
A Novel Strategy To Reduce the Immunogenicity of Biological Therapies (2010) (67)
Epidemiology and genetics of multiple sclerosis. (1992) (65)
Environmental signals regulate lineage choice and temporal maturation of neural stem cells from human embryonic stem cells. (2007) (64)
The Genetic Association of Variants in CD6, TNFRSF1A and IRF8 to Multiple Sclerosis: A Multicenter Case-Control Study (2011) (64)
Pathogenic Mitochondrial tRNA Point Mutations: Nine Novel Mutations Affirm Their Importance as a Cause of Mitochondrial Disease (2013) (62)
Surveying multiple sclerosis in the United Kingdom. (1995) (62)
An experimental model of secondary progressive multiple sclerosis that shows regional variation in gliosis, remyelination, axonal and neuronal loss (2008) (62)
MANBA, CXCR5, SOX8, RPS6KB1 and ZBTB46 are genetic risk loci for multiple sclerosis. (2013) (61)
Comparative performances of machine learning methods for classifying Crohn Disease patients using genome-wide genotyping data (2019) (61)
HLA typing in the United Kingdom multiple sclerosis genome screen (1998) (60)
Differential generation of oligodendrocytes from human and rodent embryonic spinal cord neural precursors (2004) (59)
Induction of Olig2+ Precursors by FGF Involves BMP Signalling Blockade at the Smad Level (2008) (58)
A new familial infantile form of diffuse brain-sclerosis. (2013) (58)
Confounding Underlies the Apparent Month of Birth Effect in Multiple Sclerosis (2013) (57)
Myelin repair: the role of stem and precursor cells in multiple sclerosis (2008) (56)
A Major Histocompatibility Class I Locus Contributes to Multiple Sclerosis Susceptibility Independently from HLA-DRB1*15:01 (2010) (56)
Beta-interferon and multiple sclerosis (1997) (56)
Glial lineages and myelination in the central nervous system. (1997) (55)
Association of the truncating splice site mutation in BTNL2 with multiple sclerosis is secondary to HLA-DRB1*15. (2006) (53)
Accelerated lymphocyte recovery after alemtuzumab does not predict multiple sclerosis activity (2014) (51)
Investigation of the Role of Mitochondrial DNA in Multiple Sclerosis Susceptibility (2008) (51)
Human oligodendrocytes are not sensitive to complement. A study of CD59 expression in the human central nervous system. (1995) (50)
CIITA variation in the presence of HLA-DRB1*1501 increases risk for multiple sclerosis. (2010) (50)
Interrogating the complex role of chromosome 16p13.13 in multiple sclerosis susceptibility: independent genetic signals in the CIITA-CLEC16A-SOCS1 gene complex. (2011) (49)
Affinity of antigen-specific IgG distinguishes multiple sclerosis from encephalitis (1995) (49)
Predicting autoimmunity after alemtuzumab treatment of multiple sclerosis (2013) (49)
The Neurofibromatoses. A pathogenetic and clinical overview (1994) (48)
Polyclonal immunoglobulins (IVIg) modulate nitric oxide production and microglial functions in vitro via Fc receptors (2001) (48)
Risk factors for multiple sclerosis: race or place? (1990) (48)
Multiple sclerosis in sibling pairs: an analysis of 250 families (2001) (47)
Brain Repair (1994) (47)
The natural history of multiple sclerosis (2006) (47)
The Genetic Analysis of Multiple sclerosis in EuropeanS: concepts and design (2003) (46)
Making progress on the natural history of multiple sclerosis. (2006) (45)
Oligodendroglia are protected from antibody-mediated complement injury by normal immunoglobulins (“IVIg”) (2000) (45)
Chapter 1 – The story of multiple sclerosis (2006) (45)
A genome-wide DNA microsatellite association screen to identify chromosomal regions harboring candidate genes in diabetic nephropathy. (2006) (45)
Trophic factors attenuate nitric oxide mediated neuronal and axonal injury in vitro: roles and interactions of mitogen‐activated protein kinase signalling pathways (2005) (44)
Evaluating the role of the 620W allele of protein tyrosine phosphatase PTPN22 in Crohn's disease and multiple sclerosis (2006) (44)
Interleukin 1 receptor antagonist (IL-1ra) in multiple sclerosis (2000) (44)
Sensory history. (2009) (43)
No evidence of association between mutant alleles of the CYP27B1 gene and multiple sclerosis (2013) (43)
Exploring the CLEC16A gene reveals a MS-associated variant with correlation to the relative expression of CLEC16A isoforms in thymus (2011) (43)
Magnetization transfer imaging in multiple sclerosis treated with alemtuzumab (2013) (42)
The distribution of multiple sclerosis (2006) (42)
A screen of candidates from peaks of linkage: evidence for the involvement of myeloperoxidase in multiple sclerosis (1999) (42)
IL 12 A , MPHOSPH 9 / CDK 2 AP 1 and RGS 1 are novel multiple sclerosis susceptibility loci (2010) (41)
From the Archives. (2019) (40)
A genomic screen of Spanish multiple sclerosis patients reveals multiple loci associated with the disease (2003) (40)
A genome screen for linkage disequilibrium in HLA-DRB1*15-positive Germans with multiple sclerosis based on 4666 microsatellite markers (2002) (39)
The genetic epidemiology of multiple sclerosis. (1999) (39)
A whole genome screen for linkage in Turkish multiple sclerosis (2003) (39)
Variation within DNA repair pathway genes and risk of multiple sclerosis. (2010) (38)
Genetic analysis of multiple sclerosis. (1997) (38)
Postnatal astrocytes promote neural induction from adult human bone marrow-derived stem cells. (2003) (38)
Cardiac abnormalities in chronic progressive external ophthalmoplegia. (1976) (37)
New candidate loci for multiple sclerosis susceptibility revealed by a whole genome association screen in a Belgian population (2003) (37)
A systems biology approach uncovers cell-specific gene regulatory effects of genetic associations in multiple sclerosis (2019) (36)
Evidence for abnormal tau phosphorylation in early aggressive multiple sclerosis (2009) (36)
Acting on incidental findings in research imaging (2015) (34)
The differential diagnosis of multiple sclerosis (2006) (34)
A whole genome association study in Icelandic multiple sclerosis patients with 4804 markers (2003) (34)
The role of inflammatory bowel disease susceptibility loci in multiple sclerosis and systemic lupus erythematosus (2006) (34)
Low-Frequency and Rare-Coding Variation Contributes to Multiple Sclerosis Risk (2018) (33)
CAMPATH-1H in multiple sclerosis (1996) (33)
Problems with rating scales for multiple sclerosis: a novel approach — the CAMBS score (2004) (33)
Methylprednisolone and multiple sclerosis. (1988) (33)
Abnormal tau phosphorylation in primary progressive multiple sclerosis (2010) (33)
Magnetic Resonance of Myelin, Myelination, and Myelin Disorders. 2nd Edition (1996) (32)
Genome-wide association studies in multiple sclerosis: lessons and future prospects. (2011) (32)
Remyelination of the central nervous system (1996) (32)
Regional potential for oligodendrocyte generation in the rodent embryonic spinal cord following exposure to EGF and FGF‐2 (1998) (32)
CD24 Ala/Val polymorphism and multiple sclerosis (2006) (31)
The epidemiology of multiple sclerosis: Principles, achievements, and recommendations (1994) (31)
Genetic burden in multiple sclerosis families (2013) (31)
Multiple sclerosis risk variants alter expression of co-stimulatory genes in B cells (2018) (31)
Polyclonal immunoglobulins for intravenous use do not influence the behaviour of cultured oligodendrocytes (1999) (31)
The pathogenesis and basis for treatment in multiple sclerosis (2004) (31)
Derivation of neural precursor cells from human ES cells at 3% O2 is efficient, enhances survival and presents no barrier to regional specification and functional differentiation (2011) (31)
Exploring the dense mapping of a region of potential linkage in complex disease: An example in multiple sclerosis (1999) (30)
Four single nucleotide polymorphisms from the Vitamin D Receptor Gene in UK Multiple Sclerosis (2004) (30)
A genome wide scan for association with multiple sclerosis in a N. Irish case control population (2003) (29)
Refining the analysis of a whole genome linkage disequilibrium association map: the United Kingdom results (2003) (28)
Heterogeneity at the HLA-DRB 1 locus and risk for multiple sclerosis (2006) (27)
Slowly Progressive Axonal Degeneration in a Rat Model of Chronic, Nonimmune-Mediated Demyelination (2010) (27)
A Taqman assay for high-throughput genotyping of the multiple sclerosis-associated HLA-DRB1*1501 allele. (2008) (27)
No evidence for shared genetic basis of common variants in multiple sclerosis and amyotrophic lateral sclerosis. (2014) (26)
Chance and design. (1999) (26)
Parkinson's disease — the story of an eponym (2018) (26)
Lack of support for association between the KIF1B rs10492972[C] variant and multiple sclerosis (2010) (26)
HERV-K113 is not associated with multiple sclerosis in a large family-based study. (2008) (25)
'The marvellous harmony of the nervous parts': the origins of multiple sclerosis. (2004) (25)
Minocycline attenuates nitric oxide-mediated neuronal and axonal destruction in vitro. (2004) (24)
A non-synonymous SNP within membrane metalloendopeptidase-like 1 (MMEL1) is associated with multiple sclerosis (2010) (24)
Inhibition of tumour necrosis factor‐α (TNFα)‐induced NF‐κB p52 converts the metabolic effects of microglial‐derived TNFα on mouse cerebellar neurones to neurotoxicity (2001) (24)
No evidence of a significant role for CTLA-4 in multiple sclerosis (2006) (23)
Decade of the brain. (2005) (23)
Disease-modifying treatments in multiple sclerosis (2006) (22)
A whole genome association study in Finnish multiple sclerosis patients with 3669 markers (2003) (22)
Neural stem cells as a potential source of oligodendrocytes for myelin repair (2005) (22)
A genome screen for linkage disequilibrium in Turkish multiple sclerosis (2003) (22)
Linkage disequilibrium screening for multiple sclerosis implicates JAG1 and POU2AF1 as susceptibility genes in Europeans. (2006) (21)
A genome-wide screen for linkage disequilibrium in Australian HLA-DRB1*1501 positive multiple sclerosis patients (2003) (21)
Evidence that allelic variants of the spinocerebellar ataxia type 2 gene influence susceptibility to multiple sclerosis (1999) (21)
The effect of methylprednisolone on lymphocyte phenotype and function in patients with multiple sclerosis (1990) (20)
Visual disorientation with special reference to lesions of the right cerebral hemisphere. By W. Russell Brain (From the Neurological Department, London Hospital) Brain 1941: 64; 244–272. (2007) (20)
Demyelinating disorders of the central nervous system (2010) (20)
Two genome-wide linkage disequilibrium screens in Scandinavian multiple sclerosis patients (2003) (20)
A genome-wide screen for linkage disequilibrium in Sardinian multiple sclerosis (2003) (20)
Neural Precursor Cells Cultured at Physiologically Relevant Oxygen Tensions Have a Survival Advantage Following Transplantation (2013) (19)
A whole genome screen for linkage disequilibrium in multiple sclerosis performed in a continental Italian population (2003) (19)
Evidence for CRHR1 in multiple sclerosis using supervised machine learning and meta-analysis in 12,566 individuals. (2010) (19)
Inflammation and the brain. (1993) (19)
MULTIPLE SCLEROSIS IN THE ORKNEYS (1981) (18)
Genetic analysis of multiple sclerosis (2002) (18)
Immune mechanisms in the pathogenesis of demyelinating diseases. (1989) (18)
HLA TYPING IN MULTIPLE SCLEROSIS (1982) (18)
Remyelination in multiple sclerosis: a challenge for therapy (1997) (18)
Evidence for a Type 1 diabetes‐specific mechanism for the insulin gene‐associated IDDM2 locus rather than a general influence on autoimmunity (2004) (18)
Mechanisms of axon-glial injury of the optic nerve (2004) (17)
A genome-wide screen for association in Hungarian multiple sclerosis (2003) (17)
Crohn’s associated NOD2 gene variants are not involved in determining susceptibility to multiple sclerosis (2003) (17)
Neuronal expression of pathological tau accelerates oligodendrocyte progenitor cell differentiation (2015) (17)
A genome-wide German screen for linkage disequilibrium in multiple sclerosis (2003) (17)
Future prospects for the management of multiple sclerosis (1994) (17)
A whole genome screen for association in Polish multiple sclerosis patients (2003) (17)
The basis for treatment in multiple sclerosis (2006) (16)
The Genetics of Multiple Sclerosis (2000) (16)
A whole genome screen for association with multiple sclerosis in Portuguese patients (2003) (16)
Limiting and repairing the damage in multiple sclerosis. (1991) (15)
Multiple sclerosis treatment trial precipitates divorce (2001) (14)
Case reports in The Lancet (2003) (14)
Durable Efficacy of Alemtuzumab in Relapsing-Remitting Multiple Sclerosis Patients Who Participated in the CARE-MS Studies: Three Year Follow-Up (S41.001) (2013) (14)
Chapter 3 – The genetics of multiple sclerosis (2006) (14)
A whole genome association study in multiple sclerosis patients from north Portugal (2003) (14)
Recurrent myelitis and optic neuritis in a 29-year-old woman (2005) (13)
No evidence for the involvement of interleukin 2 or the immunoglobulin heavy chain gene cluster in determining genetic susceptibility to multiple sclerosis (2000) (13)
SELPLG and SELP single-nucleotide polymorphisms in multiple sclerosis (2006) (13)
Myelination in vitro of rodent dorsal root ganglia by glial progenitor cells. (1994) (13)
Genetic analysis of multiple sclerosis in Europeans: French data (2003) (13)
Complexity and heterogeneity in demyelinating disease. (2007) (13)
Oligodendroglial‐derived stress signals recruit microglia in vitro (2003) (13)
Low-Frequency and Rare-Coding Variation Contributes to Multiple Sclerosis Risk (2020) (13)
LUPUS ANTICOAGULANT: A PLACE FOR PRE-PREGNANCY TREATMENT? (1985) (12)
A ‘‘Candidate-Interactome’’ Aggregate Analysis of Genome-Wide Association Data in Multiple Sclerosis (2013) (12)
Doctors who write literature may be considered to have crossed from science to the humanities obtaining release from the rigid constraints of logic, experiment and fact, and gaining the freedoms of imagination, metaphor and fiction. (2009) (12)
Allelic association of sequence variants in the herpes virus entry mediator-B gene (PVRL2) with the severity of multiple sclerosis (2006) (11)
Genetic Susceptibility and Epidemiology (2004) (11)
Multiple Sclerosis: Light at the end of the tunnel (2006) (11)
Refining the linkage analysis on chromosome 10 in 449 sib-pairs with multiple sclerosis (2003) (10)
From the archives. Corticobasal degeneration. By WRG Gibb, PJ Luther and CD Marsden. Brain 1989: 112; 1171-1192 with Corticobasal degeneration. A clinical study of 36 cases. By JO Rinne, MS Lee, PD Thompson and CD Marsden. Brain 1994: 117; 1183-1196. (2010) (10)
Action recognition in the premotor cortex. By Vittorio Gallese, Luciano Fadiga, Leonardo Fogassi and Giacomo Rizzolatti. Brain 1996: 119; 593–609. (2009) (10)
A clear case of possession. Editorial. (2010) (10)
Queen Square: A History of the National Hospital and its Institute of Neurology (2018) (9)
Susceptibility to multiple sclerosis and the immunoglobulin heavy chain gene cluster (1998) (9)
Polymorphisms in the neuromyelitis optica auto-antigen AQP4 and susceptibility to multiple sclerosis (2007) (9)
Origins of gliogenic stem cell populations within adult skin and bone marrow. (2010) (9)
No evidence for association of multiple sclerosis with the complement factors C6 and C7 (1999) (9)
A genome wide linkage disequilibrium screen in Parkinson’s disease (2005) (9)
Ultraconserved regions in multiple sclerosis (2005) (9)
Efficacy and Safety Results from Comparison of Alemtuzumab and Rebif(R) Efficacy in Multiple Sclerosis II (CARE-MS II): A Phase 3 Study in Relapsing-Remitting Multiple Sclerosis Patients Who Relapsed on Prior Therapy (S01.004) (2012) (8)
No evidence for association of a European-specific chromosome 17 inversion with multiple sclerosis (2006) (8)
HLA and neurologic disease (1978) (8)
The structure and functions of the cerebellum examined by a new method. By Sir Victor Horsley, FRS, FRCS and R.H. Clarke, MA, MB. Brain 1908: 31; 45–124. (2007) (8)
Future options for therapies to limit damage and enhance recovery. (1998) (8)
Etymology and the neuron(e) (2019) (8)
Advances in Clinical Neuroscience & Rehabilitation (2005) (8)
Chapter 16 – Treatment of the acute relapse (2006) (8)
Double-blind randomized multicenter dose-comparison study of interferon-β-1a (AVONEX): rationale, design and baseline data (2001) (8)
Product licences for alemtuzumab and multiple sclerosis (2014) (7)
Efficacy and Safety Results from Comparison of Alemtuzumab and Rebif® Efficacy in Multiple Sclerosis I (CARE-MS I): A Phase 3 Study in Relapsing-Remitting Treatment-Naïve Patients (S01.006) (2012) (7)
Exome sequencing in single cells from the cerebrospinal fluid in multiple sclerosis (2014) (7)
Multiple Sclerosis and Myasthenia Gravis (1985) (7)
Minimally manipulated oligodendrocyte precursor cells retain exclusive commitment to the oligodendrocyte lineage following transplantation into intact and injured hippocampus (2007) (7)
Transcript specific regulation of expression influences susceptibility to multiple sclerosis (2019) (7)
Effect of Alemtuzumab vs. Rebif(R) on Brain MRI Measurements: Results of CARE-MS I, a Phase 3 Study (S11.006) (2012) (6)
Brain repair: an overview (1994) (6)
Immunogenicity of Alemtuzumab Treatment in Relapsing-Remitting Multiple Sclerosis (RRMS) Patients in the CARE-MS II Study (P07.101) (2013) (6)
INTERFERON BETA IN MULTIPLE SCLEROSIS. AUTHOR'S REPLY (1999) (6)
Chapter 5 – The origins of multiple sclerosis: a synthesis (2006) (6)
Adverse Event Profile of Alemtuzumab over Time in Active Relapsing-Remitting Multiple Sclerosis Patients Who Experienced Disease Activity While on Prior Therapy (CARE-MS II) (P01.174) (2013) (5)
Commentary: Scheme has benefited patients (2010) (5)
More evidence that founder effects exist in the European population (1999) (5)
Quantitative management of contraction in lowest level co-ordination. Hughlings Jackson Lecture.(Given January 29, 1931). By C.S. Sherrington. Brain 1931: 54; 1–28 (2006) (5)
No evidence for association between an MAOA functional polymorphism and susceptibility to Parkinson’s disease (2009) (5)
Aphasia and artistic realization (being the Harveian lecture of the Harveian Society, delivered March 17th 1948) by Th. Alajouanine. Brain 1948: 71; 229–241. (2007) (5)
Durable Effect of Alemtuzumab on Clinical Outcomes in Treatment-Naive Relapsing-Remitting Multiple Sclerosis Patients: Four-Year Follow-up of CARE-MS I (S4.007) (2015) (5)
Predicting Autoimmunity Following Treatment of Multiple Sclerosis with Alemtuzumab (2010) (5)
Provision of treatment for multiple sclerosis (1999) (5)
Chapter 14 – The pathogenesis of multiple sclerosis: a pandect (2006) (4)
The genetics of multiple sclerosis. (2000) (4)
Alemtuzumab Reduces MS Disease Activity in Active Relapsing-Remitting Multiple Sclerosis Patients Who Had Disease Activity on Prior Therapy (P07.093) (2013) (4)
Brain. Editorial. (2010) (4)
Bilateral ballistic movements occurring as a late complication of hemispherectomy and responding to sulpiride (1986) (4)
The cerebral blood-vessels in health and disease. By Prof. H. Obersteiner (Vienna). Brain 1884: 7; 289–309 (Translated from the original manuscript by C.E. Beevor, MD). (2007) (4)
The modern management of multiple sclerosis. (1986) (4)
Mechanisms of damage and repair in multiple sclerosis — a review (1995) (4)
Chapter 17 – The treatment of symptoms in multiple sclerosis and the role of rehabilitation (2006) (4)
Professor P. K. Thomas: clinician, investigator, editor and leader--a retrospective appreciation. (2011) (4)
Optic neuritis as a sentinel lesion to study neuroprotection and repair in a trial of autologous mesenchymal stem cells in multiple sclerosis (2008) (4)
A human experiment in nerve division by W.H.R. Rivers MD FRS, Fellow of St John's College, Cambridge and Henry Head MD FRS, Physician to the London Hospital, Brain 1908: 31; 323-450. (2009) (4)
Cellular organisation of the optic nerve and the implications for optic neuritis (1992) (4)
The structural basis of traumatic epilepsy and results of radical operation. By O. Foerster, Breslau, and Wilder Penfield, Montreal. Brain 1930; 53: 99-119. (2017) (4)
Corrigendum to “Linkage disequilibrium screening for multiple sclerosis implicates JAG1 and POU2AF1 as susceptibility genes in Europeans” [J. Neuroimmunol. 179 (2006) 108–116] (2007) (4)
Care of the person with multiple sclerosis (2006) (3)
From the archives. The cerebral arterial supply. By Charles E Beevor MD, FRCP. Brain 1908; 30: 403–25. (2013) (3)
Using common genetic variants to find drugs for common epilepsies (2021) (3)
The pathological anatomy of the lesion in multiple sclerosis (1999) (3)
More on Cetuximab in Head and Neck Cancer (2007) (3)
Novel Olig 1-coding variants and susceptibility to multiple sclerosis (2006) (3)
From The Archives (1982) (3)
Reviewing multiple sclerosis. (1992) (3)
War-neurasthenia, acute and chronic. By DW Carmalt Jones MD FRCP, Physician to Westminster Hospital; sometime Medical Officer-in-charge Medical Division, No. 4 Stationary Hospital, British Expeditionary Force (Neurological centre), and Consultant Physician, Egyptian Expeditionary Force. Brain 1919; (2013) (3)
Beta-Interferon and multiple sclerosis: not a final solution to the problem. (1995) (3)
150th anniversary of clinical description of multiple sclerosis (2018) (3)
On aphasia due to atrophy of the cerebral convolutions. By Dr G. Mingazzini, Professor of Neuropathology at the Royal University of Rome. Brain 1914: 36; 493–524. (2008) (3)
Incidence of Autoimmunity in a Phase 3 Trial: Comparison of Alemtuzumab and Rebif(R) in Multiple Sclerosis I (CARE-MS I) (S41.006) (2012) (3)
From the archives. 'Visual field changes following anterior temporal lobectomy: their significance in relation to "Meyer's loop" of the optic radiation' and 'The architecture of the optic radiation in the temporal lobe of man'. (2005) (3)
Multiple sclerosis: A Conceptual Reappraisal with Heuristic Implications (1990) (3)
Lymphocyte subpopulations inpatients withmultiple sclerosis (1983) (3)
Here there are lions (2011) (3)
Author Correction: A systems biology approach uncovers cell-specific gene regulatory effects of genetic associations in multiple sclerosis (2019) (3)
Relapse Outcomes with Alemtuzumab vs IFNB-1a in Active Relapsing-Remitting Multiple Sclerosis Patients Who Experienced Disease Activity While on Prior Therapy (CARE-MS II) (P07.098) (2013) (3)
Revisiting The pathogenesis of multiple sclerosis revisited. (2003) (3)
Brain. Editorial. (2011) (2)
Infections in Phase 3 Study: Comparison of Alemtuzumab and Rebif(R) Efficacy in Multiple Sclerosis I (CARE-MS I) (S41.007) (2012) (2)
No evidence for association of the protein kinase C alpha gene with multiple sclerosis (2005) (2)
'All manner of ingenuity and industry' (2021) (2)
Multiple Sclerosis: a Guide for Patients and their Families (1984) (2)
Brain. Editorial. (2011) (2)
The enigma of Gerstmann’s syndrome (The William Gowers lecture delivered on 2 December 1965). By Macdonald Critchley. Brain 1966: 89; 183–198 (2010) (2)
Relapse Outcomes with Alemtuzumab vs. Rebif® in Treatment-Naïve Relapsing-Remitting Multiple Sclerosis (CARE-MS I): Secondary and Tertiary Endpoints (PD5.004) (2012) (2)
The hippocampus and the sense of smell. A review, by Alf Brodal. Brain 1947: 70; 179-222. (2010) (2)
Interferon beta in multiple sclerosis (1999) (2)
Hemichorea resulting from a local lesion of the brain. (The syndrome of the body of Luys.) (2006) (2)
Chapter 6 Genetics of Multiple Sclerosis (2003) (2)
Chapter 9 – Multiple sclerosis in the individual and in groups: a conspectus (2006) (2)
Efficacy of Alemtuzumab vs IFNB-1a in Relapsing-Remitting Multiple Sclerosis Patients Who Experienced Disease Activity While on Prior Therapy (CARE-MS II): Subgroup Analysis by Previous Disease Modifying Therapy (DMT) Use (P07.111) (2013) (2)
'All manner of ingenuity and industry': A bio-bibliography of Thomas Willis 1621 - 1675 (2021) (2)
Chapter 19 – The person with multiple sclerosis: a prospectus (2006) (2)
On the weight of the brain and its component parts in the insane. By J. Crichton-Browne, MD, FRSE, Lord Chancellor's Visitor. Brain 1879: 1; 514–518 and 1879: 2; 42–67. (2007) (2)
Dorsal column. (2014) (2)
Switching to Alemtuzumab From Subcutaneous Interferon Beta-1a After CARE-MS II Further Improved MRI Outcomes in Patients With Relapsing-Remitting Multiple Sclerosis (P7.248) (2015) (2)
Dr Macdonald Critchley (1900-97). (2010) (2)
Texture of the Nervous System of Man and the Vertebrates by Santiago Ramon y Cajal. Volume 1. (2001) (2)
A particular variety of headache. By Sir Charles Symonds (From Guy's Hospital and the National Hospital, Queen Square, London). Brain 1956: 79; 217–232 (2008) (2)
Reply: The etymology of 'neurology', redux: early use of the term by Jean Riolan the Younger (1610). (2021) (1)
Microscopical observations on the cerebral circulation of the blood in the cerebral cortex, by Howard Florey (BA and John Lucas Walker Student; From the Physiological Laboratory, Oxford and Pathological Laboratory, Cambridge). Brain 1925: 48; 43–64 (2010) (1)
Brain. Editorial. (2011) (1)
Chapter 10 – The neurobiology of multiple sclerosis (2005) (1)
MANAGEMENT OF ADVERSE REACTIONS TO ALEMTUZUMAB INFUSION (2015) (1)
Brain Repair (1995) (1)
Sir Henry Head FRS (1861–1940): a life in science and society (2017) (1)
Semantic dementia. Progressive fluent aphasia with temporal lobe atrophy. By John R. Hodges, Karalyn Patterson, Susan Oxbury and Elaine Furnell. From The Archives. (2011) (1)
46. Limiting and repairing the damage in multiple sclerosis (2010) (1)
Cerebrospinal fluid had come a long way since Galen of Pergamon (130–200) declared the ventricles to be reservoirs for the animal spirits. (2015) (1)
The Health and Future of Academic Neurology (2002) (1)
Brain. Editorial. (2012) (1)
William Ian McDonald: 1933-2006. (2011) (1)
Calman Cometh (1996) (1)
Brain. Editorial. (2013) (1)
From the archives. Problems of life and mind. (2005) (1)
Myelination, demyelination and remyelination (2002) (1)
Explorer Induction of Olig 2 precursors by FGF involves BMP signalling blockade at the Smad level (2017) (1)
Brain editorial. (2013) (1)
What got me into neurology (and did it work out?) (2010) (1)
Selection of patients for clinical trials. (1987) (1)
Brain denies being forbidding and insensitive to change (2002) (1)
Acute poliomyelitis. By F. E. Batten MD Cantab FRCP Lond. The Lumleian Lectures for 1916 delivered before the Royal College of Physicians. Brain 1916; 39: 115-211. (2016) (1)
Update on disease modifying therapies in MS (2014) (1)
Retinal venous sheathing in optic neuritis: its significance for the pathogenesis of multiple sclerosis. By S. Lightman, W. I. McDonald, A. C. Bird, D. A. Francis, A. Hoskins, J. R. Batchelor and A. M. Halliday. Brain 1987: 110; 405–414 (2010) (1)
Neurodegeneration caused by intronic expansions of C9ORF72 is a clinically heterogeneous but pathologically distinct disease (2013) (1)
Antibody therapy of multiple sclerosis (2007) (0)
Willis and the cortical neuron (2021) (0)
Introduction and approach to the patient with neurological disease (2020) (0)
Spastic pseudosclerosis (cortico-pallido-spinal degeneration), by Charles Davison (New York), Brain 1932: 55; 247–264 and Severe dementia associated with bilateral symmetrical degeneration of the thalamus, by K. Stern (From the National Hospital, Queen Square, London), Brain 1939: 62; 157–171. (2009) (0)
Lord Campbell's account of Shakespeare's legal knowledge stimulated Sir John (Charles) Bucknill to interpret the bard's words and phrases of medical significance for the general reader. Editorial. (2009) (0)
‘Addicted to the opening of heads’ (2021) (0)
Brain. Editorial. (2010) (0)
‘The whole dowry of all nature’ (2021) (0)
Brain. Editorial. (2013) (0)
Brain. Editorial. (2011) (0)
Dorsal column. From the archives. (2014) (0)
Editorial. 'The muddle of embodiment'. (2009) (0)
Communications of the European Neurological Society (2000) (0)
The Oxford dictionary of medical quotations (2004) (0)
Characterising the Adult Human Oligodendrocyte Progenitor (1997) (0)
Inflammation, Demyelination, and Axonal Degeneration: Three Aspects of the Pathogenesis of Multiple Sclerosis Revealed by Campath-1H Treatment (2004) (0)
'Primary sensory neuropathy with muscular changes associated with carcinoma'. Editorial. (2009) (0)
25. Aetiology and origins of multiple sclerosis (2010) (0)
Facial reflexes. (2005) (0)
Many organizations and institutions will celebrate the bicentenary of the birth of Charles Darwin. Editorial. (2009) (0)
Immune-Mediated Brain Injury and Repair: Mechanisms and Therapies (2001) (0)
Brain. Editorial. (2013) (0)
Brain Editorial. (2012) (0)
Misrepresentation of the outside world or self may follow damage to the nervous system. (2008) (0)
The150th anniversary ofthefirst depiction ofthe lesions ofmultiple sclerosis (1988) (0)
‘To practice medicine with a safe conscience’ (2021) (0)
‘Setting down experiments of the sciences’ (2021) (0)
Brain. Editorial. (2012) (0)
Brain, Cosmopolitan and the BMJ (2017) (0)
Immunogenicity of Biological Therapies A Novel Strategy To Reduce the (2010) (0)
Pocket Book of Clinical Neurology (1980) (0)
The lipidoses and the central nervous system. 1948. (2012) (0)
From the archives. A contribution to the study of apraxia with a review of the literature. (2013) (0)
Brain. Editorial. (2011) (0)
New policy on manuscripts (1989) (0)
Brain. Editorial. (2012) (0)
Was Charles Darwin interested in the brain? (2009) (0)
Brain. Editorial. (2011) (0)
Brain. Editorial. (2011) (0)
Disturbed perception of colours associated with localized cerebral lesions. By J. C. Meadows (From the National Hospital for Nervous Diseases, Queen Square, London WCIN 3BG) Brain 1974: 97; 615–632. (2008) (0)
Brain. Editorial. (2010) (0)
Editorial. Sarcasm, risk taking, callous unemotional responses, confabulation, telling lies, gambling, fear-conditioning and compulsive activity. (2009) (0)
‘A certain physiologie and pathology of the brain and nervous stock’ (2021) (0)
Measurements come in all shapes and sizes. (2009) (0)
Thomas Willis - His life and times (2021) (0)
From the archives. (2013) (0)
Brain. Editorial. (2011) (0)
Neurosurgery and War Neurology at Queen Square (2018) (0)
Clinics in Immunology and Allergy, Vol 2, No 2 “Immunoneuropathology” (1983) (0)
The 15th Rappaport Symposium. Immune-mediated brain injury and repair: mechanisms and therapies. 15-16 June 2000, Haifa, Israel. (2001) (0)
Viruses and Demyelinating Diseases (1986) (0)
Brain. Editorial. (2009) (0)
Brain. Editorial. (2012) (0)
HEREDITARY DIFFUSE LEUKOENCEPHALOPATHY WITH SPHEROIDS INSIGHTS INTO AN ADULT ONSET NEURODEGENERATIVE DISEASE (2013) (0)
Brain. Editorial. (2010) (0)
‘To be avoided as if they were sick’ (2021) (0)
Brain. Editorial. (2011) (0)
Occasional essay: Multiple sclerosis in the digital age: ‘seeing through a glass darkly’ (2020) (0)
In Memoriam Kenneth Till FRCS (2008) (0)
Brain. Editorial. (2010) (0)
Progressive dystrophy of the external ocular muscles (ocular myopathy). By L. G. Kiloh and S. Nevin (From the Neurological Department, King's College Hospital.) Brain 1951: 74; 115–143. (2008) (0)
The harmony of the brain (2014) (0)
Explorer Origins of Gliogenic Stem Cell Populations Within Adult Skin and Bone Marrow (2017) (0)
Brain. Editorial. (2012) (0)
From the archives. (2014) (0)
Disability Improvement with Alemtuzumab vs. Interferon beta-1a in Relapsing-Remitting Multiple Sclerosis Patients Who Experienced Disease Activity While on Prior Therapy (CARE-MS II) (P07.120) (2013) (0)
Editorial note (2004) (0)
Brain. Editorial. (2013) (0)
Alemtuzumab (Campath-1H) (2016) (0)
‘A great and difficult thing, and full of hazard’ (2021) (0)
John Walton, Lord Walton of Detchant: a man of influence and goodwill. (2016) (0)
Brain. Editorial. (2011) (0)
B-Cell Depletion for Treatment of Primary Progressive Multiple Sclerosis (2010) (0)
Brain. Editorial. (2012) (0)
Brain. Editorial. (2008) (0)
Anita Harding (17 September 1952–11 September 1995) (1996) (0)
Never, Never, Ever – Change and Integration 1962–1997 (2018) (0)
‘To delineate with most skillful hands’ (2021) (0)
Brain. Editorial. (2013) (0)
Brain. Editorial. (2010) (0)
Evidence for an immune response within the central nervous system in multiple sclerosis (0)
Communications of the European Neurological Society (2008) (0)
From the Archives (1982) (0)
Brain. Editorial. (2012) (0)
‘Satisfying a mind desirous of truth’ (2021) (0)
From the Archives (1981) (0)
Brain. Editorial. (2013) (0)
Brain. Editorial. (2011) (0)
The anatomy and physiology of cutaneous sensibility: a critical review. By FMR Walshe. Brain 1942: 65; 48–112. (2011) (0)
Brain. Editorial. (2012) (0)
‘Those first forgotten particles’ (2021) (0)
Brain. Editorial. (2011) (0)
From the Archives (1983) (0)
Brain. Editorial. (2012) (0)
Advanced General Medicine Conference Joint Conference of Sultan Qaboos University and the Ministry of Health, Oman Gastrointestinal Endocrinology (2011) (0)
LONG-TERM SAFETY OF ALEMTUZUMAB IN RELAPSING-REMITTING MULTIPLE SCLEROSIS: PREGNANCY AND INFECTION DATA FROM A COHORT OF PATIENTS ON OPEN LABEL STUDIES IN CAMBRIDGE (2015) (0)
Brain. Editorial. (2010) (0)
Deceptively amorphous macroscopic appearance of the brain conceals untold complexities of regional specification. (2008) (0)
Dr. Sigmund Freud. Editorial. (2010) (0)
On the structure and functional relations of the optic thalamus. By Ernest Sachs, A.B., MD, of New York. From Sir Victor Horsley's Laboratory, Department of Pathological Chemistry, University College, London. Brain 1909: 32; 95–186. (2007) (0)
Brain. Editorial. (2005) (0)
The physical basis for cutaneous sensation (1988) (0)
Science and religion traditionally part company around the issue of evidence. (2008) (0)
Brain. Editorial. (2013) (0)
‘Of drudgery in pursuit of lucre’ (2021) (0)
Rationale for the use of multipotent mesenchymal stromal cells in multiple sclerosis (2008) (0)
Brain. Editorial. (2013) (0)
Introduction (2021) (0)
Clinical Neurology (1952) (0)
Comparative performances of machine learning methods for classifying Crohn Disease patients using genome-wide genotyping data (2019) (0)
Human chromosome 18q12-q21 and distal rodent chromosome 18 are associated with multiple autoimmune phenotypes. (1999) (0)
Verbal fluency as a brief clinical screening tool for cognitive impairment in multiple sclerosis: an alternative to the Paced Auditory Serial Addition Test? (2008) (0)
Brain. Editorial. (2008) (0)
The cerebral basis of consciousness. By W. Russell Brain. Brain 1950: 73; 465-479; and The physiological basis of consciousness. A critical review by Russell Brain. Brain 1958: 81; 426–455. (2009) (0)
Brain. Editorial. (2013) (0)
Brain. Editorial. (2010) (0)
Transcript specific regulation of expression influences susceptibility to multiple sclerosis (2020) (0)
Brain. Editorial. (2012) (0)
Cis acting expression loci in multiple sclerosis (2005) (0)
FUNCTIONAL HUMAN ES-DERIVED OPCS AT LOW OXYGEN (2014) (0)
Dorsal column. From the archives. (2014) (0)
Brain. Editorial. (2010) (0)
Down the ages, physicians have observed the evolution of disease over time. (2013) (0)
Sensory radicular neuropathy associated with muscle wasting in two cases (2006) (0)
The Investigatory Specialties at Queen Square (2018) (0)
‘In the tents of the King as well as the Muses’ (2021) (0)
Balanced and responsible journalism. (2009) (0)
It is part of the art of medicine that, despite its origins in organ based pathological anatomy, the concept of 'disease' is constantly adjusted by evolving societal concepts of what does and does not constitute illness. (2009) (0)
National Hospital Quadrumvirate (2018) (0)
Contribution Variation Within DNA Repair Pathway Genes and Risk of Multiple Sclerosis (2010) (0)
PL05-TU-01 Immunogenetics and epidemiology of multiple sclerosis (Fulton Symposium Soriano Lecture) (2009) (0)
Investigation of novel type 1 diabetes loci in multiple sclerosis (2009) (0)
‘An Iliad of evils in the head’ (2021) (0)
Surveying multiple sclerosis in the United Kingdom [Editorial] (1995) (0)
Brain. Editorial. (2008) (0)
The problem of disseminated sclerosis (being the Presidential Address of the Neurological Section, Royal Society of Medicine, October 1946). By Douglas McAlpine. Brain 1946: 69; 233–250. (2008) (0)
The role of the CD[subscript 5]8 locus in multiple sclerosis (2009) (0)
Preface to the fourth edition (2006) (0)
‘Neurologie: the doctrine of the nerves’ (2021) (0)
THE EVOLVING MS LANDSCAPE: CHALLENGES AND OPPORTUNITIES Summary of Presentations from the Genzyme-Sponsored Symposium, held at the Joint Congress of European Neurology (2014) (0)
Brain. Editorial. (2005) (0)
oligodendrocytes in vitro upon exposure to notochord or SHH , and following transplantation (0)
Brain. Editorial. (2012) (0)
Most intact human nervous systems know whether they are vertical or tilted, to around 4 degrees of accuracy between the perceived and real displacement. (2008) (0)
The evolution of consciousness. Together with a diagram illustrating certain homologies in the nervous system. By W.H.B. Stoddart MD MRCP. Brain 1903; 26: 432-439. With The structure of consciousness by Michael Polanyi. Brain 1965; 88: 799-810. (2017) (0)
Evidence that allelic variants of the spinocerebellar ataxia genes may contribute to multiple sclerosis susceptibility. (1999) (0)
BOOK REVIEWS (1994) (0)
Genome-wide meta-analysis identifies novel multiple sclerosis susceptibility loci | NOVA. The University of Newcastle's Digital Repository (2011) (0)
‘The hearths and altars for the vital fire’ (2021) (0)
Brain. Editorial. (2008) (0)
Designing Clinical Trials to Test Neuroprotective Therapies in Multiple Sclerosis (2013) (0)

This paper list is powered by the following services:

Other Resources About Alastair Compston

en.wikipedia.org

What Schools Are Affiliated With Alastair Compston?

Alastair Compston is affiliated with the following schools:

Alastair Compston's Academic­Influence.com Rankings